Assessment of verdinexor as a canine P-glycoprotein substrate.
Sign Up to like & getrecommendations! Published in 2023 at "Journal of veterinary pharmacology and therapeutics"
DOI: 10.1111/jvp.13123
Abstract: The P-glycoprotein (P-gp) substrate status of antineoplastic drugs intended for veterinary patients is an important characteristic to define for two reasons. First, neoplastic cells expressing P-gp can actively efflux drugs that are P-gp substrates curtailing… read more here.
Keywords: verdinexor; canine; antineoplastic drugs; glycoprotein substrate ... See more keywords
THU0241 LUPUS PROGRESSION IS PREVENTED BY TREATMENT WITH VERDINEXOR, AN INHIBITOR OF THE NUCLEAR EXPORT PROTEIN EXPORTIN-1, BY LIMITING GERMINAL CENTER FORMATION AND DEVELOPMENT OF AUTOREACTIVE ANTIBODY SECRETING CELLS
Sign Up to like & getrecommendations! Published in 2019 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2019-eular.3092
Abstract: Background Systemic lupus erythematosus (SLE) is a complex autoimmune disease characterized by simultaneous activation of the innate and adaptive arms of the immune system. Recently the nuclear export protein exportin-1 (XPO1) has surfaced as an… read more here.
Keywords: antibody secreting; verdinexor; sine compounds; nuclear export ... See more keywords